Cannabis, marijuana and Hemp stock news from Investorideas.com plus daily cannabis #potcasts - Investor Ideas #Potcasts #Cannabis News and Stocks on the Move
Vermont Senate Approves Bill to Regulate #Marijuana
for Adult Use and Eliminate Penalties for Home Cultivation
Statement
below from Matt Simon of the Marijuana Policy Project
MONTPELIER,
Vt. - April 21, 2017 (Investorideas.com Newswire) The Vermont Senate approved a
bill on Friday that would regulate the production and sale of marijuana and
eliminate penalties for personal possession and cultivation by adults 21 and
older.
The
Senate amended H. 167, an unrelated House-approved bill, to replace it with a
revised version of a marijuana regulation bill that passed last year in the
Senate and failed in the House. The Senate also amended H. 167 to include the
same home cultivation provision that is included in H. 170, a bill that has
been making its way through the House. H. 170 would eliminate Vermont's civil
penalty for possessing one ounce or less of marijuana and remove penalties for
possession of up to two mature marijuana plants and up to four immature plants.
The Senate proposal would allow unlimited small-scale cultivation licenses for
producers no larger than 500 sq feet. The marijuana regulation bill that failed
in the House last year, S. 241, did not include a home cultivation provision.
The
Senate-amended version of H. 167 will receive one final vote before being sent
back to the House for consideration.
Most
Vermont voters are in favor of the policy changes proposed in H. 167 and H.
170, according to a survey conducted March 20-21 by Public Policy Polling.
Fifty-seven percent support allowing adults 21 and older to possess and grow
limited amounts of marijuana, and 54% support regulating and taxing marijuana
similarly to alcohol. The results are available athttps://www.mpp.org/VTpoll.
Statement
from Matt Simon, New England political director for the Marijuana Policy
Project:
"Most
Vermonters think marijuana should be made legal for adults, and they're looking
to lawmakers to come up with a plan. We applaud the Senate for approving a thoughtful
alternative to marijuana prohibition that would account for public health and
improve public safety. We would love to see the House step up and join the
Senate in supporting this sensible reform. If the House isn't willing to
support the Senate's proposal, it at least needs to support its own Judiciary
Committee's plan and pass H. 170."
The
Vermont Coalition to Regulate Marijuana is a broad coalition of citizens,
organizations, and businesses working to end marijuana prohibition in Vermont
and replace it with a system in which marijuana is regulated and taxed. For
more information, visithttp://www.RegulateVermont.org.
This
news is published on the Investorideas.com Newswire - a global digital news
source for investors and business leaders
Disclaimer/Disclosure:Investorideas.com
is a digital publisher of third party sourced news, articles and equity
research as well as creates original content, including video, interviews and
articles. Original content created by investorideas is protected by copyright
laws other than syndication rights. Our site does not make recommendations for
purchases or sale of stocks, services or products. Nothing on our sites should
be construed as an offer or solicitation to buy or sell products or securities.
All investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global
Investors: Effective September 15 2008 - all BC investors should review all OTC
and Pink sheet listed companies for adherence in new disclosure filings and
filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
This Week’s Cannabis and Hemp
Stocks Added; $DVA.V; $SVSN
Other New Marijuana/Hemp Stocks: ASX: ZLD, BOT, CPH, MDC
Point Roberts, WA, Delta BC – April 21, 2017 –
Investorideas.com, a global news source and investor resource covering actively
traded sectors announces this week’s additions to its cannabis /hemp stock directory for investors
following the sector.
Australian listed (ASX) stocks are at the forefront
of this week’s additions with 4 new stocks being added that include a company
involved in medical cannabis for treatment of a variety of ailments; a cannabis-based
medicine for oncology; cannabidiol treatment for psoriasis and atopic dermatitis and Creso Pharma Limited
(ASX:CPH.AX) a leader in cannabidiol (CBD) innovation, currently developing
cannabis and hemp‐derived therapeutic‐grade Nutraceuticals and Medical Cannabis
products with a broad range of applications in both human and animal health.
Also new this week are Delivra Corp. (TSX:DVA.V) is a specialty biotechnology company who
recently completed a strategic
partnership with Dosecann Inc. and ARA-Avanti RX Analytics Inc. to develop a
unique suite of standardized and commercialized products for the medical
cannabis market and Stereo Vision Entertainment, Inc. (OTC:SVSN) a
media company who is also the majority owner of medical cannabis and organic
hemp subsidiary, MediCannaVision Inc., dba CannaVision.
Botanix Pharmaceuticals Ltd. (ASX:BOT.AX) mission is to improve the lives of patients battling acne, psoriasis
and atopic dermatitis, by providing new treatment options for conditions that
currently are inadequately addressed or are treated with therapeutics that are
burdened with side effects profiles. We are harnessing the untapped potential
of a synthetic active pharmaceutical ingredient known as cannabidiol which is
currently being studied for the treatment of epilepsy, pain, arthritis and
schizophrenia amongst other indications. Botanix is preparing for the first
human trials utilizing synthetic cannabidiol in a proprietary drug delivery
system (Permetrex™) for direct skin delivery of the therapy.
Creso
Pharma Limited (ASX:CPH.AX) pharmaceutical expertise and methodological rigour to the world of
medical cannabis and strives for the highest quality in its products,
leveraging science and research in order to develop, register and commercialise
innovative therapeutic approaches targeting the endocannabinoid system. Creso
Pharma is a leader in cannabidiol (CBD) innovation, developing cannabis- and
hemp‐derived therapeutic‐grade Nutraceuticals and Medical Cannabis products with a broad range of
applications in both human and animal health. Creso Pharma’s innovative CBD
fully plant-based nutraceutical products are non-psychoactive, as they contain
only trace amounts of THC. Focusing on unique and innovative product delivery
systems, Creso Pharma is developing therapeutic products and nutraceuticals
manufactured according to the highest GMP standards, and maintaining the
highest levels of compliance across the supply chain. Creso Pharma holds
worldwide rights for a number of proprietary innovative delivery technologies
which enhance the bioavailability and absorption of cannabinoids. Furthermore,
Creso Pharma’s standardised dosage forms are specifically designed and adapted
for human health and for animal health, and for several medical conditions
including pain and anxiety disorders, metabolic disorders and inflammatory
disorders.
Delivra
Corp. (TSX:DVA.V) is a specialty biotechnology company that has a proprietary
transdermal delivery system platform that can shuttle pharmaceutical and
natural molecules, through the skin, in a targeted specific manner. Delivra
manufactures and sells a growing line of natural topical creams with the
proprietary transdermal delivery system platform under the LivRelief™ brand,
for conditions such as joint and muscle pain, nerve pain, varicose veins, wound
healing, and under the LivSport™ brand for sports performance. LivRelief™
products are available in pharmacies, grocery chains, and independent health
food stores across Canada, and on-line at www.livrelief.com. LivRelief™ pain
and nerve pain products are also available in the United States on Amazon and
at www.livrelief.com/us. In parallel with its consumer products business,
Delivra also has a mandate to license its patent-pending proprietary
transdermal delivery technology platform to pharmaceutical companies globally,
for the repurposing of pharmaceutical molecules transdermally to treat a broad
range of conditions, along with licensing its over-the-counter products
globally. Delivra is headquartered in Burlington, Ontario and has a research
and development laboratory in Charlottetown, PEI. Cannabis:Completed a strategic partnership with Dosecann Inc. and ARA-Avanti RX
Analytics Inc. to develop a unique suite of standardized and commercialized
products for the medical cannabis market
Medlab
Clinical Ltd. (ASX:MDC.AX) l is an Australian based medical life science
company, with a certified biologics facility in Sydney and sales arms in
Australia and California. Medlab’s research relates to five health areas -
obesity, chronic kidney disease, depression, ageing and muscular skeletal
health and pain management. A lot of Medlab’s research is on the role bacteria
in the gastrointestinal tract play in health and disease, leading to drug
discovery and development of new medicines involving bacteria (pharmacobiotics)
as well as nutritional products. Medlab is also about to commence a human trial
of a cannabis-based medicine for oncology patients with intractable pain,
utilising its small particle medicine delivery system, Nanocelle™. Medlab has a
growing patent portfolio, multiple published research papers and conference
presentations and the Pharmacobiotic trademark – a therapeutic term referring
to both probiotics and biologics.
Stereo
Vision Entertainment, Inc. (OTC:SVSN) is a publicly traded Nevada company focused on creating, acquiring,
and producing multimedia content with its media subsidiaries the majority owned
family entertainment company Inspirational Vision Media and the wholly
owned 9 time Emmy Award winning production company REZN8, and the
majority owned medical cannabis and organic hemp subsidiary, MediCannaVision
Inc., dba CannaVision.
Zelda Therapeutics Limited (ASX:ZLD.AX) has been formed to bring together some of the world’s leading
researchers and clinicians active in the study and use of medicinal cannabis to
treat a variety of ailments.
The complete marijuana/hemp stock list available for purchase in a PDF
format:
Investorideas.com tracks companies in high profile
trading sectors and makes ongoing additions to its stock directories for each
sector. Listing for the stock directories include companies on the
TSX, OTC, NYSE, NASDAQ and global stock exchanges.
Investorideas.com global stock directories are part
of the membership program on the site, accessed either by login and password or
available in PDF format. The directories include stocks trading on the
TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving
retail investors a wide variety of stocks to review.http://www.investorideas.com/membership/
The directories are not meant as recommendations
but as a research tool to discover opportunities and trading ideas in a
particular sector.
About
Investorideas.com - News that Inspires Big Ideas
Investorideas.com
is a meeting place for global investors, featuring news, stock directories,
video, podcasts, company profiles, interviews and more in leading sectors.
Sectors we cover include
tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water
stocks, marijuana and hemp stocks, food and beverage (including organic and
LOHAS, wine), defense and security (including biometrics), Latin America,
sports, entertainment, luxury brands and gaming.
The Investorideas.com
content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence
(AI) websites on the Grid and the Waternewswire.com, all featuring
Investorideas.com news and content.
Disclaimer/Disclosure:
Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution,social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global
Investors: Effective September 15 2008 - all BC investors should review all OTC
and Pink sheet listed companies for adherence in new disclosure filings and
filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to
regulations of each country.
Canadian
Cannabis Stock News: Aphria (TSX: $APH) (OTCQB: $APHQF) Raises $100 Million to
Fund Continued Expansion of Production Capacity and Other Strategic
Opportunities
LEAMINGTON, ONTARIO - April 20, 2017
(Investorideas.com Newswire) NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE
SERVICES OR DISSEMINATION IN THE UNITED STATES - Aphria Inc. ("Aphria"
or the "Company") (TSX:APH) (OTCQB:APHQF), a Health Canada Licensed
Producer of medical cannabis products, announced today that it has secured a
$100 million raise, including a $75 million bought deal equity financing and
$25 million in debt financing through a five-year term loan. This is the first
time Aphria has raised both debt and equity simultaneously.
The Company expects that 50% of the
net proceeds of the Offering will be allocated towards the currently unfunded
portion of Part IV Expansion, with the balance being allocated between the
working capital necessary to support the Company once the Part IV expansion is
complete and strategic investments.
"This fund raising is a
testament to the confidence of the investment community in Aphria's success to
date and our vision for the future," said Vic Neufeld, Chief Executive
Officer, Aphria.
"Through this raise, we are not
only looking at the needs of today, but what Aphria is going to need to do in
the years ahead to dominate the market. When completed in 2018, our four-part
expansion plan is expected to supply more than 75,000 kg of high-quality
cannabis at one of the lowest costs in the industry. We are well positioned to
continue to provide shareholder value and meet the increasing consumer demand
for medical and recreational marijuana," said Mr. Neufeld.
As part of the raise, Aphria entered
into an agreement with Clarus Securities Inc., on behalf of a syndicate of
underwriters (collectively, the "Underwriters"), pursuant to which
the Underwriters have agreed to purchase, on a "bought deal" basis,
11,538,480 Common Shares (the "Common Shares") of the Company at a
price of $6.50 per Common Share (the "Offering Price") for aggregate
gross proceeds to the Company of $75,000,120 (the "Offering").
The Company has agreed to grant the
Underwriters an over-allotment option to purchase up to an additional 1,730,772
Common Shares at the Offering Price, exercisable in whole or in part at any
time for a period ending 30 days from the closing of the Offering. In the event
the over-allotment option is exercised in full, the aggregate gross proceeds of
the Offering will be $86,250,138.
The Common Shares will be offered by
way of a short form prospectus to be filed in each of the provinces of Canada,
other than the Province of Quebec, and in those jurisdictions outside of Canada
and the United States which are agreed to by the Company and the Underwriters,
where the Common Shares can be issued on a private placement basis, exempt from
any prospectus, registration or other similar requirements. The deal is
expected to close on May 9, 2017 and is subject to certain conditions
including, but not limited to, the receipt of all necessary approvals,
including the approval of the TSX.
The securities have not been, and
will not be, registered under the United States Securities Act of 1933, as
amended (the "U.S. Securities Act"), or any U.S. state securities
laws, and may not be offered or sold in the United States without registration
under the U.S. Securities Act and all applicable state securities laws or
compliance with the requirements of an applicable exemption therefrom. This
press release shall not constitute an offer to sell or the solicitation of an
offer to buy securities in the United States, nor shall there be any sale of
these securities in any jurisdiction in which such offer, solicitation or sale
would be unlawful.
The remaining portion of the raise is
comprised of a 5-year, $25 million term loan with WFCU Credit Union
("WFCU") bearing interest at 3.95% and a 15-year amortization
("Debt Financing"). The facility will be entered into on May 9, 2017.
The term loan is secured by a first charge on the Company's real estate
holdings, a first position on a general security agreement, certain cash
security and an assignment of fire insurance to the lender.
About Aphria
Aphria Inc., one of Canada's lowest
cost producers, produces, supplies and sells medical cannabis. Located in
Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered
by sunlight, allowing for the most natural growing conditions available. We are
committed to providing pharma-grade medical cannabis, superior patient care
while balancing patient economics and returns to shareholders. We are the first
public licensed producer to report positive cash flow from operations and the
first to report positive earnings in consecutive quarters.
We Have a Good Thing Growing.
For more information, visit
www.aphria.com.
CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTS: Certain information in this news release
constitutes forward-looking statements under applicable securities laws. Any
statements that are contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements. Forward looking
statements are often identified by terms such as "may",
"should", "anticipate", "expect",
"potential", "believe", "intend" or the negative
of these terms and similar expressions. Forward-looking statements in this news
release include, but are not limited to, statements with respect to internal
expectations, estimated margins, completion of the Debt Financing, timing for
completion of final TSX approval, expectations for future growing capacity and
costs, the completion of any capital project or expansions, any commentary
related to the legalization of marijuana and the timing related thereto,
expectations of Health Canada approvals and expectations with respect to future
production costs. Forward-looking statements necessarily involve known and
unknown risks, including, without limitation, risks associated with general
economic conditions; adverse industry events; marketing costs; loss of markets;
future legislative and regulatory developments involving medical marijuana;
inability to access sufficient capital from internal and external sources,
and/or inability to access sufficient capital on favourable terms; the medical
marijuana industry in Canada generally, income tax and regulatory matters; the
ability of Aphria to implement its business strategies; competition; crop failure;
currency and interest rate fluctuations and other risks.
Readers are cautioned that the
foregoing list is not exhaustive. Readers are further cautioned not to place
undue reliance on forward-looking statements as there can be no assurance that
the plans, intentions or expectations upon which they are placed will occur.
Such information, although considered reasonable by management at the time of
preparation, may prove to be incorrect and actual results may differ materially
from those anticipated.
Forward-looking statements contained
in this news release are expressly qualified by this cautionary statement.
This news is published on the
Investorideas.com Newswire - a global digital news source for investors and
business leaders
Disclaimer/Disclosure:Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
VOD Channel Offers Collection of Content
Covering All Things Cannabis
Los Angeles - April 20, 2017 (Investorideas.com Newswire)
Recognizing the increasing entrenchment of cannabis in the global zeitgeist,
420 Entertainment Group, comprised of OWNZONES Media Network, the upstart
global OTT technology/entertainment hybrid company, along with cannabis
entrepreneurs Genesis Media and Alex Nahai Enterprises (ANE), will launch
420TV, a new video-on-demand channel, hailing the wonders of weed.
420TV will feature original, multi-episodic series, as well as
long- and short-form news, information and entertainment content focusing on
all things cannabis. All content will be shot in 4K.
The
announcement was made today by Dan Goman, CEO at OWNZONES, and Alex Nahai, CEO
at ANE.
Available this fall through the OWNZONES.com platform, 420TV is
the first premium 4K video-on-demand network to tap into cannabis' growing
prominence in today's mainstream lifestyle. Cannabis is projected to be a $44
billion industry in the next three years, according to Marijuana Daily News.
420TV expects to attract viewers across generations, ranging
from millennials to boomers who are either curious about or converted to the
cannabis lifestyle. While the channel will launch on OWNZONES.com, and its
mobile applications, it will quickly expand through OWNZONES' worldwide
multi-platform distribution network, utilizing the full spectrum of OWNZONES'
capabilities, including programming, technology and global distribution.
"The nation's evolving laws, growing interest and changing
attitudes have created a multitude of opportunities to educate, entertain and
expand public acceptance of cannabis, in all of its various applications,"
said Goman. "As a hybrid technology and entertainment company, OWNZONES is
uniquely positioned to capitalize on the explosive growth of the marijuana
industry. We have found the ideal partner in Genesis with years of expertise
and credibility in the cannabis business and will provide 420TV a real inside
perspective in this burgeoning space."
"This is an industry with many benefits, and we are
creating an effective and engaging means for promoting established companies
and new brands to consumers. 420TV will provide that connection. The 4K video
on-demand service is just the beginning – we intend to establish 420TV as a
franchise brand for multiple lines of related businesses," Nahai added.
420TV's news, information and entertainment programming
currently in development includes:
Pot Cast – Daily news programming chronicling the advent of the
legal marijuana industry. With a team of 60 journalists nationwide, Pot Cast
will present short-form news segments on the political, business, financial and
cultural aspects surrounding the disruptive rise of this new industry.
Signature segments include "Pot-Counter-Pot" and "This Week in
Pot History."
Medical Marijuana Miracles – True stories of real people who
have used medical marijuana for unique relief of symptoms and diseases.
Marijuana Moguls – Fascinating series about the bold new
entrepreneurs emerging in the cannabis industry.
Cannabis 411 – An informative and educational series covering
every step from how to grow weed to how to consume it.
Doug Lee, OWNZONES Programming Head, will oversee the original
programming line-up and manage the day-to-day business of 420TV. Lee is a
seasoned media executive with over 25 years of experience in global
entertainment, having held senior programming and channel positions at HBO,
News Corp. and MGM Studios.
420TV will deliver dozens of hours of original programming
produced exclusively for the multi-platform channel, in addition to acquired
long and short form entertainment. Other content categories in development
include fashion, comedy, music and animation as well as acquired feature films,
documentaries, music and live streaming events.
Genesis Media is a content creation and media company founded by
the principals of one of the largest medical marijuana cultivation and
distribution companies in the United States, and dedicated to the proliferation
of information regarding cannabis through television and digital media
platforms.
About
Alex Nahai Enterprises
Alex Nahai Enterprises is a full-service entertainment and
branding company, founded by Alex Nahai, an entrepreneur with thirteen years of
experience in the music, television, digital media, and branding industries.
About
OWNZONES Media Network
OWNZONES Media Network is a leading hybrid technology and
entertainment company and a global provider of technology and media solutions
for the motion picture, television and digital content creation industries. The
company's proprietary technology platform and integrated marketing and
programming services offer content owners a single-source, end-to-end solution
for delivering world class viewing experiences across all OTT platforms
including web, mobile apps and connected devices. It also produces its own
original programming targeting millennials and distributes content through its
worldwide networks. Its clients include Comcast, Magnolia Pictures, British
Pathe, Scripps, Amazon, SonyVue, Roku, CenturyLink, and Apple TV among others.
OWNZONES offers direct-to-consumer streaming video in the form
of OWNZONES.com, a channel-customizable VOD platform. For more information
please visitwww.ownzonesmedia.com.
Media
Contacts:
Priority PR
Jeff Pryor
e. jeff@prioritypr.net; 818-661-6368 x 4
Kristien Brada-Thompson
e. kristien@prioritypr.net; 818-661-6368 x 2
This news is published on the
Investorideas.com Newswire - a global digital news source for investors and
business leaders
Disclaimer/Disclosure:Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
